多西他赛联合顺铂治疗晚期头颈部肿瘤的效果观察

Abstract
Figure/Table
References (15)
Related Citation (8)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe clinical efficacy and toxicity of Docetaxel plus Cisplatin in treatment of patients with advanced head and neck cancer.Methods 58 patients with advanced head and neck cancer in our hospital from December 2013 to December 2015 were divided into observation group(n=30)and control group(n=28)according to different treatment regimen.Patients in the observation group were given with Docetaxel plus Cisplatin treatment regimen, patients in the control group received Fluorouracil plus Cisplatin treatment regimen.The clinical efficacy and toxicity after a month were evaluated and compared between two groups after treatment for one month.Results The response rate in the observation group was 66.7%,higher than 39.3%in the control group,and the difference was statistically significant(P＜0.05).The toxicities of two groups were mainly gastrointestinal reactions,bone marrow suppression,and incidence of gastrointestinal reactions and bone marrow suppression in observation group was obviously lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion Patients with advanced head and neck cancer treated by Docetaxel plus Cisplatin chemotherapy can get a more satisfactory clinical efficacy and mild toxicity and it should be introduced in clinical practice.

Key words： Docetaxel Cisplatin Advanced head and neck cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yun
	LUO Le
	HE Qian
	ZHANG Lin
	HAN Ya-qian
	LIU Feng
	LIU Lin
	MA Hong-zhi

Cite this article:

LI Yun,LUO Le,HE Qian, et al. Observation of clinical efficacy of Docetaxel plus Cisplatin in treatment of patients with advanced head and neck cancer[J]. 中国当代医药, 2016, 23(30): 62-64.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I30/62

[1]	宿伟鹏，赵化荣.头颈部肿瘤治疗进展[J].新疆医科大学学报，2013，36（2）：259-265.
[3]	赵颖，王芮.抗肿瘤药物多西他赛研究进展[J].中国药业，2014，24（10）：87-89.
[4]	杨学宁，吴一龙.实体瘤治疗疗效评价标准——RECⅠST [J].循证医学，2004，4（2）：85-90.
[2]	Chou WW，Puri DR，Lee NY.Ⅰntensity-modulated radiation therapy for head and neck cancer[J].Expert Rev Anticancer Ther，2005，5（3）：515-521.
[5]	佚名.抗癌药急性及亚急性毒性反应分度标准（WHO标准）[J].癌症，1992，11（3）：253-255.
[6]	郑登云，杨丽辉，管吉林.2015年头颈部肿瘤研究进展[J].循证医学，2016，16（1）：25-26.
[7]	Edefonti V，Hashibe M，Parpinel M，et al.Natural vitamin C intake and the risk of head and neck cancer：a pooled analysis in theⅠnternational Head and Neck Cancer Epidemiology Consortium[J].Br J Cancer，2015，113（1）：182-192.
[8]	李科，章一新.氟尿嘧啶相关化疗方案及常见不良反应[J].肿瘤研究与临床，2014，26（4）：275-279.
[9]	郑慧.紫杉醇联合顺铂化疗方案治疗晚期食道癌的临床观察[J].中国现代药物应用，2014，8（12）：115-116.
[10]	Moloney EC，Brunner M，Alexander AJ，et al.Quantifying fibrosis in head and neck cancer treatment：an overview[J]. Head Neck，2015，37（8）：1225-1231.
[11]	舒诚荣，曹爱玲，张峰，等.多西他赛联合顺铂序贯放化疗对局部晚期喉癌的疗效分析[J].华南国防医学杂志，2015，33（6）：448-450.
[12]	梁宁震，韩宏斌，晏党.顺铂联合替吉奥治疗晚期头颈部肿瘤的临床疗效观察[J].中国医药指南，2014，12（28）：163.
[13]	Chen SH，Kuo CC，Li CF，et al.O(6)-methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma[J].Ⅰnt J Cancer，2015，137（6）：1291-1305.
[14]	金永东，梅开，陈萍，等.多西他赛联合顺铂治疗晚期头颈部肿瘤的疗效观察[J].肿瘤基础与临床，2013，26（3）：243-244.
[15]	Ford HE，Marshall A，Bridgewater JA，et al.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma（COUGAR-02）：an open-label，phase 3 randomised controlled trial[J].Lancet Oncol，2014，15（1）：78-86.